Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03646617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Study acronym: RadVax
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Enrollment increased: 54 → 62 participants · Primary completion moved earlier from Jun 30, 2026 to Mar 21, 2026 · Site details revised at 3 of 3 sitesv16 Show 3 more changesShow less
    • Enrollment increased: 54 → 62 participants
    • Primary completion moved earlier from Jun 30, 2026 to Mar 21, 2026
    • Site details revised at 3 of 3 sites
  2. Primary completion date: Jun 30, 2025 to Jun 30, 2026 Completion date: Dec 31, 2026 to Dec 31, 2027v15 Show 1 more changeShow less
    • Completion date: Dec 31, 2026 to Dec 31, 2027
  3. Enrollment target: 52 to 54v14
  4. Primary completion date: Jun 30, 2024 to Jun 30, 2025 Completion date: Dec 31, 2025 to Dec 31, 2026v13 Show 1 more changeShow less
    • Completion date: Dec 31, 2025 to Dec 31, 2026
  5. Eligibility criteria expanded, about 15 wordsv12 See this version in full on ClinicalTrials.gov ↗
Show 10 earlier versionsHide 10 earlier versions
  1. Site details revised at 1 of 3 sitesv11
  2. Study sites: 2 to 3v10
  3. Collaborators expanded, about 4 wordsv9 See this version in full on ClinicalTrials.gov ↗
  4. Start date: Aug 23, 2018 to Nov 27, 2018 Primary completion date: Feb 23, 2024 to Jun 30, 2024 · Completion date: Feb 23, 2025 to Dec 31, 2025v8 Show 2 more changesShow less
    • Primary completion date: Feb 23, 2024 to Jun 30, 2024
    • Completion date: Feb 23, 2025 to Dec 31, 2025
  5. Study sites: 1 to 2v7
  6. Primary completion date: Feb 23, 2022 to Feb 23, 2024 Completion date: Feb 23, 2023 to Feb 23, 2025v6 Show 1 more changeShow less
    • Completion date: Feb 23, 2023 to Feb 23, 2025
  7. Enrollment target: 70 to 52 Eligibility criteria expanded, about 12 wordsv5 Show 1 more changeShow less
    • Eligibility criteria expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

  8. Trial status: Active, Not Recruiting to Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  9. Trial status: Recruiting to Active, Not Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  10. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
Trial Details
NCT Number NCT03646617
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Melanoma
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov